Dogecoin Cash, Inc. (DOGP)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Dogecoin Cash, Inc. (DOGP) with AI Score 46/100 (Weak). Dogecoin Cash, Inc. operates in the telemedicine and cannabis industries, providing online referral services for medical marijuana cards. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Dogecoin Cash, Inc. (DOGP) Healthcare & Pipeline Overview
Dogecoin Cash, Inc. focuses on telemedicine services for medical marijuana recommendations through its PrestoDoctor platform, targeting the cannabidiol and cannabis industries. The company develops related products like lozenges and topical creams, and intends to offer fashion apparel through its website, operating in a competitive and evolving regulatory landscape.
Investment Thesis
Dogecoin Cash, Inc. presents a high-risk, high-reward investment profile due to its focus on the evolving cannabis telemedicine market. The company's PrestoDoctor platform offers a direct-to-consumer approach for medical marijuana recommendations, potentially capitalizing on increasing acceptance and legalization trends. However, the company's negative P/E ratio of -1.65 and a profit margin of -195.0% indicate significant financial challenges. Growth catalysts include expanding PrestoDoctor's reach to new states and launching planned fashion apparel lines. Key risks involve regulatory hurdles, competition from established telemedicine providers, and the company's limited operating history. Investors should carefully consider the volatile nature of the cannabis industry and Dogecoin Cash, Inc.'s financial position before investing.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B, indicating a micro-cap company with limited financial resources.
- P/E ratio of -1.65, reflecting net losses and potentially unsustainable operations.
- Gross margin of 63.4%, suggesting a strong ability to control production costs relative to revenue.
- Profit margin of -195.0%, indicating significant operational inefficiencies and high expenses.
- Beta of 2.78, indicating high volatility compared to the overall market.
Competitors & Peers
Strengths
- Established PrestoDoctor platform for telemedicine consultations.
- Intellectual property license for medical marijuana edibles.
- Focus on the growing cannabis and telemedicine industries.
- Direct-to-consumer approach for medical marijuana recommendations.
Weaknesses
- Negative P/E ratio and profit margin indicate financial challenges.
- Limited operating history and small employee base.
- Dependence on evolving regulatory landscape.
- Intense competition from established telemedicine providers.
Catalysts
- Upcoming: Potential expansion of PrestoDoctor into new states legalizing medical marijuana.
- Upcoming: Launch of branded men's and women's fashion apparel through www.cbds.com.
- Ongoing: Increasing acceptance and legalization of medical marijuana in the United States.
- Ongoing: Growing demand for telemedicine services for convenient healthcare access.
Risks
- Potential: Changes in regulations and legal restrictions on cannabis could negatively impact operations.
- Potential: Competition from larger and more established telemedicine companies.
- Ongoing: Negative P/E ratio and profit margin indicate financial instability.
- Potential: Limited access to capital and funding opportunities.
- Ongoing: High price volatility and illiquidity due to OTC listing.
Growth Opportunities
- Expansion into New States: Dogecoin Cash, Inc. has the opportunity to expand its PrestoDoctor platform into new states as medical marijuana legalization progresses. Each new state represents a potential market for its telemedicine services. The timeline for this expansion depends on the legislative landscape in each state, but successful entry into key markets could significantly boost revenue and market share. This expansion would require navigating different regulatory environments and tailoring its services to meet local requirements.
- Development of New Cannabis-Related Products: The company's development of lozenges, balms, and creams represents a growth opportunity. By introducing innovative and targeted products, Dogecoin Cash, Inc. can attract new customers and increase revenue streams. The market for cannabis-infused products is expanding, with consumers seeking various forms of consumption and therapeutic benefits. The timeline for product development and launch depends on research, formulation, and regulatory approvals.
- Expansion of the www.cbds.com Website: Dogecoin Cash, Inc.'s plan to offer branded men's and women's fashion apparel through its www.cbds.com website represents a diversification strategy. By leveraging its existing online platform and customer base, the company can tap into the broader e-commerce market. The timeline for launching the fashion apparel line depends on sourcing suppliers, designing products, and setting up the online store. Success in this venture would require effective marketing and branding efforts.
- Leveraging Intellectual Property for Edibles: Holding an intellectual property license for the manufacture of medical marijuana edibles provides Dogecoin Cash, Inc. with a unique opportunity. The edibles market is a significant segment of the cannabis industry, offering a discreet and convenient consumption method. By developing and marketing its own line of edibles, the company can capture a share of this growing market. The timeline for launching edibles depends on production capacity, regulatory compliance, and market demand.
- Partnerships with Cannabis Dispensaries: Dogecoin Cash, Inc. can explore partnerships with cannabis dispensaries to offer its PrestoDoctor services to their customers. By integrating its telemedicine platform with dispensaries' online or in-store operations, the company can reach a wider audience and streamline the process of obtaining medical marijuana recommendations. The timeline for establishing partnerships depends on negotiations, integration efforts, and mutual benefits.
Opportunities
- Expansion into new states as medical marijuana legalization progresses.
- Development of new cannabis-related products.
- Expansion of the www.cbds.com website to include fashion apparel.
- Partnerships with cannabis dispensaries.
Threats
- Changing regulations and legal restrictions on cannabis.
- Competition from larger and more established telemedicine companies.
- Potential for negative publicity or reputational damage.
- Economic downturn impacting consumer spending on cannabis products.
Competitive Advantages
- First-mover advantage in providing telemedicine services for medical marijuana recommendations.
- Established PrestoDoctor platform with existing user base and physician network.
- Intellectual property license for the manufacture of medical marijuana edibles.
- Brand recognition within the cannabis telemedicine market.
About DOGP
Dogecoin Cash, Inc., formerly known as Cannabis Sativa, Inc. until its name change in November 2024, is a healthcare information services company providing telemedicine solutions within the cannabis industry. The company's core offering is PrestoDoctor, an online platform that facilitates virtual consultations between patients and physicians for medical marijuana recommendations. Utilizing video conferencing technology, PrestoDoctor aims to streamline the process of obtaining medical marijuana cards for eligible individuals in the United States. Beyond its telemedicine platform, Dogecoin Cash, Inc. develops and markets cannabis-related products, including lozenges designed for relief, Recover, a deep penetrating healing balm, and Trauma Cream, a cannabinoid and THC-infused cream. The company also holds an intellectual property license for the manufacture of medical marijuana edibles. Additionally, Dogecoin Cash, Inc. intends to expand its offerings to include branded men's and women's fashion apparel sourced from suppliers, to be sold through its www.cbds.com website. Headquartered in Mesquite, Nevada, Dogecoin Cash, Inc. serves both the cannabidiol (CBD) and cannabis markets, navigating the complex regulatory environment surrounding these industries.
What They Do
- Provides telemedicine online referral services for customers desiring medical marijuana cards.
- Offers PrestoDoctor, an online telemedicine platform connecting patients with physicians.
- Facilitates video conferencing for medical marijuana recommendations.
- Develops lozenges for relief.
- Produces Recover, a deep penetrating healing balm for pain relief.
- Creates Trauma Cream, a cream infused with cannabinoids and THC.
- Intends to offer branded men's and women's fashion through www.cbds.com.
- Holds intellectual property license for manufacture of medical marijuana edibles.
Business Model
- Generates revenue through fees charged for telemedicine consultations on the PrestoDoctor platform.
- Sells cannabis-related products, including lozenges, balms, and creams, directly to consumers.
- Plans to generate revenue from the sale of branded fashion apparel through its online store.
- Potentially licenses its intellectual property for medical marijuana edibles to other companies.
Industry Context
Dogecoin Cash, Inc. operates within the rapidly evolving cannabis and telemedicine industries. The cannabis market is experiencing significant growth, driven by increasing legalization and acceptance of medical and recreational marijuana. Telemedicine is also expanding, fueled by technological advancements and a growing demand for remote healthcare services. Dogecoin Cash, Inc. aims to capitalize on the intersection of these two trends by providing online medical marijuana recommendations. However, the company faces competition from established telemedicine providers and other cannabis-focused businesses. The industry is also subject to complex and changing regulations, which can impact Dogecoin Cash, Inc.'s operations and growth prospects.
Key Customers
- Individuals seeking medical marijuana cards for various health conditions.
- Patients looking for convenient and accessible telemedicine consultations.
- Consumers interested in cannabis-related products for pain relief and other therapeutic benefits.
- Customers of cannabis dispensaries seeking medical marijuana recommendations.
- Individuals interested in purchasing branded fashion apparel through the company's online store.
Financials
Chart & Info
Dogecoin Cash, Inc. (DOGP) stock price: Price data unavailable
Latest News
No recent news available for DOGP.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DOGP.
Price Targets
Wall Street price target analysis for DOGP.
MoonshotScore
What does this score mean?
The MoonshotScore rates DOGP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David Tobias
CEO
David Tobias is the CEO of Dogecoin Cash, Inc. He is responsible for managing the company's overall strategy and operations. With a small team of 4 employees, Tobias oversees the development and execution of the company's business plan. His background includes experience in the cannabis and telemedicine industries. He is focused on expanding the PrestoDoctor platform and launching new products.
Track Record: Under David Tobias's leadership, Dogecoin Cash, Inc. has focused on expanding its PrestoDoctor platform and developing new cannabis-related products. He led the company through its name change from Cannabis Sativa, Inc. to Dogecoin Cash, Inc. in November 2024. His strategic decisions aim to capitalize on the growing cannabis and telemedicine markets.
DOGP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Dogecoin Cash, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity may be sporadic. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for fraud or manipulation due to lack of regulatory oversight.
- High price volatility and illiquidity.
- Limited access to capital and funding opportunities.
- Going concern risk due to financial challenges.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Monitor trading volume and price activity for signs of manipulation.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Operation of the PrestoDoctor platform suggests a functional business.
- Development of cannabis-related products indicates ongoing product development efforts.
- Holding an intellectual property license for medical marijuana edibles provides some validation.
- Company has been in operation since before 2024, indicating some business history.
DOGP Healthcare Stock FAQ
What does Dogecoin Cash, Inc. do?
Dogecoin Cash, Inc. operates primarily in the cannabis telemedicine sector, offering online referral services for individuals seeking medical marijuana cards through its PrestoDoctor platform. This platform connects patients with physicians via video conferencing for medical marijuana recommendations. In addition to its telemedicine services, the company develops and markets cannabis-related products, including lozenges, balms, and creams. Dogecoin Cash, Inc. also intends to expand its offerings to include branded fashion apparel through its online store, www.cbds.com, and holds an intellectual property license for the manufacture of medical marijuana edibles.
What do analysts say about DOGP stock?
As of 2026-03-16, there is no available analyst coverage for Dogecoin Cash, Inc. (DOGP). The company's micro-cap status and OTC listing likely contribute to the lack of analyst attention. Investors should conduct their own thorough research and due diligence before considering an investment in DOGP. Key valuation metrics, such as the P/E ratio of -1.65 and a profit margin of -195.0%, suggest significant financial challenges. Growth considerations include the potential expansion of PrestoDoctor into new states and the launch of new products.
What are the main risks for DOGP?
Dogecoin Cash, Inc. faces several significant risks, including regulatory uncertainty surrounding the cannabis industry, intense competition from established telemedicine providers, and its own financial instability. Changes in regulations and legal restrictions on cannabis could negatively impact the company's ability to operate and generate revenue. The company's negative P/E ratio and profit margin indicate a need for improved financial performance. Additionally, the company's OTC listing and small market capitalization contribute to high price volatility and illiquidity, making it difficult to buy or sell shares at desired prices.
What are the key factors to evaluate for DOGP?
Dogecoin Cash, Inc. (DOGP) currently holds an AI score of 46/100, indicating low score. Key strength: Established PrestoDoctor platform for telemedicine consultations.. Primary risk to monitor: Potential: Changes in regulations and legal restrictions on cannabis could negatively impact operations.. This is not financial advice.
How frequently does DOGP data refresh on this page?
DOGP prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven DOGP's recent stock price performance?
Recent price movement in Dogecoin Cash, Inc. (DOGP) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established PrestoDoctor platform for telemedicine consultations.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider DOGP overvalued or undervalued right now?
Determining whether Dogecoin Cash, Inc. (DOGP) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying DOGP?
Before investing in Dogecoin Cash, Inc. (DOGP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- Financial data based on available information, which may be incomplete.